PF-04518600 selectively binds and activates OX40 to induce proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigen (TAA), this may promote T cell-mediated immune responses against TAA-expressing tumor cells. Indications targeted are metastatic renal cancer, triple-negative breast cancer, and advanced malignancies, respectively. Here, TNFRSF4 is linked to triple-negative breast carcinoma.